CTPI2 Improves 3-Month Healthspan in Aged Mice by Suppressing Senescence-Linked Inflammation
Updated
Updated · Nature.com · Jul 29
CTPI2 Improves 3-Month Healthspan in Aged Mice by Suppressing Senescence-Linked Inflammation
1 articles · Updated · Nature.com · Jul 29
Summary
Aged mice given CTPI2 for 3 months showed lower frailty scores, stronger grip and hanging performance, better tightrope results, and healthier muscle structure, while bone microarchitecture did not improve.
CTPI2 works by inhibiting SLC25A1, the mitochondrial citrate exporter, cutting cytosolic acetyl-CoA and histone acetylation at SASP genes, which dampened inflammatory output without reversing senescent cell-cycle arrest.
Single-nucleus multiome data from quadriceps showed senescent-like cells remained at similar abundance, but their SASP transcription and chromatin accessibility fell; liver staining likewise showed reduced nuclear acetylation in p16+/p21+ non-proliferative cells.
Cell and mouse experiments indicate SASP requires two cooperating inputs—mtDNA-cGAS-STING inflammatory signaling and mitochondrial metabolic support—while human tissue datasets linked higher SLC25A1 expression to stronger senescence-associated inflammatory signatures.
If aging is just an epigenetic inflammatory alarm, what happens when we permanently silence the siren?
Will a new drug that disarms aging cells outpace traditional treatments by preserving their hidden healing powers?
Targeting Mitochondrial Metabolism with CTPI-2: The 2026 Breakthrough in Senomorphic Therapy for Inflammaging and Chronic Disease
Overview
CTPI-2 is a new drug that targets the mitochondrial citrate carrier SLC25A1, blocking the export of citrate from mitochondria to the cytosol. This action reduces cytosolic citrate, which in turn lowers the production of acetyl-CoA needed for histone acetylation and gene regulation. In senescent cells, this metabolic-epigenetic pathway is overactive and drives chronic inflammation, known as inflammaging. By inhibiting SLC25A1, CTPI-2 suppresses harmful inflammatory signals, improves metabolic health, and delays physical frailty in animal models. In cancer, CTPI-2 also makes tumor cells more sensitive to DNA-damaging therapies. As of 2026, CTPI-2 is still in preclinical testing.